Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives.

Provins L, Christophe B, Danhaive P, Dulieu J, Gillard M, Quéré L, Stebbins K.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3077-80.

PMID:
17398090
2.

First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives.

Provins L, Christophe B, Danhaive P, Dulieu J, Durieu V, Gillard M, Lebon F, Lengelé S, Quéré L, van Keulen B.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1834-9.

PMID:
16439121
3.

Benzofuran based PDE4 inhibitors.

McGarry DG, Regan JR, Volz FA, Hulme C, Moriarty KJ, Djuric SW, Souness JE, Miller BE, Travis JJ, Sweeney DM.

Bioorg Med Chem. 1999 Jun;7(6):1131-9.

PMID:
10428384
4.

Substituted furans as inhibitors of the PDE4 enzyme.

Perrier H, Bayly C, Laliberté F, Huang Z, Rasori R, Robichaud A, Girard Y, Macdonald D.

Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6.

PMID:
10091677
5.

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Macdonald D, Mastracchio A, Perrier H, Dubé D, Gallant M, Lacombe P, Deschênes D, Roy B, Scheigetz J, Bateman K, Li C, Trimble LA, Day S, Chauret N, Nicoll-Griffith DA, Silva JM, Huang Z, Laliberté F, Liu S, Ethier D, Pon D, Muise E, Boulet L, Chan CC, Styhler A, Charleson S, Mancini J, Masson P, Claveau D, Nicholson D, Turner M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6.

PMID:
16168647
6.

2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.

Regan J, Bruno J, McGarry D, Poli G, Hanney B, Bower S, Travis J, Sweeney D, Miller B, Souness J, Djuric S.

Bioorg Med Chem Lett. 1998 Oct 6;8(19):2737-42.

PMID:
9873613
7.

Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.

Ducharme Y, Friesen RW, Blouin M, Côté B, Dubé D, Ethier D, Frenette R, Laliberté F, Mancini JA, Masson P, Styhler A, Young RN, Girard Y.

Bioorg Med Chem Lett. 2003 Jun 2;13(11):1923-6.

PMID:
12749899
8.

Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.

Nam G, Yoon CM, Kim E, Rhee CK, Kim JH, Shin JH, Kim SH.

Bioorg Med Chem Lett. 2001 Mar 12;11(5):611-4.

PMID:
11266153
9.

Orally active indole N-oxide PDE4 inhibitors.

Hulme C, Mathew R, Moriarty K, Miller B, Ramanjulu M, Cox P, Souness J, Page KM, Uhl J, Travis J, Labaudiniere R, Huang F, Djuric SW.

Bioorg Med Chem Lett. 1998 Nov 3;8(21):3053-8.

PMID:
9873675
10.

Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.

Napoletano M, Norcini G, Pellacini F, Marchini F, Morazzoni G, Ferlenga P, Pradella L.

Bioorg Med Chem Lett. 2001 Jan 8;11(1):33-7.

PMID:
11140727
11.

Synthesis and biological studies of catechol ether type derivatives as potential phosphodiesterase (PDE) IV inhibitors.

Rhee CK, Kim JH, Suh BC, Xiang MX, Youn YS, Bang WY, Kim E, Shin JK, Lee Y.

Arch Pharm Res. 1999 Apr;22(2):202-7.

PMID:
10230513
12.

8-Methoxyquinolines as PDE4 inhibitors.

Billah M, Buckley GM, Cooper N, Dyke HJ, Egan R, Ganguly A, Gowers L, Haughan AF, Kendall HJ, Lowe C, Minnicozzi M, Montana JG, Oxford J, Peake JC, Picken CL, Piwinski JJ, Naylor R, Sabin V, Shih NY, Warneck JB.

Bioorg Med Chem Lett. 2002 Jun 17;12(12):1617-9.

PMID:
12039575
13.

Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.

Frenette R, Blouin M, Brideau C, Chauret N, Ducharme Y, Friesen RW, Hamel P, Jones TR, Laliberté F, Li C, Masson P, McAuliffe M, Girard Y.

Bioorg Med Chem Lett. 2002 Oct 21;12(20):3009-13.

PMID:
12270195
14.

8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.

Whitehead JW, Lee GP, Gharagozloo P, Hofer P, Gehrig A, Wintergerst P, Smyth D, McCoull W, Hachicha M, Patel A, Kyle DJ.

J Med Chem. 2005 Feb 24;48(4):1237-43.

PMID:
15715490
15.

Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.

Napoletano M, Norcini G, Pellacini F, Marchini F, Morazzoni G, Fattori R, Ferlenga P, Pradella L.

Bioorg Med Chem Lett. 2002 Jan 7;12(1):5-8.

PMID:
11738561
16.

Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.

Vergne F, Bernardelli P, Lorthiois E, Pham N, Proust E, Oliveira C, Mafroud AK, Royer F, Wrigglesworth R, Schellhaas J, Barvian M, Moreau F, Idrissi M, Tertre A, Bertin B, Coupe M, Berna P, Soulard P.

Bioorg Med Chem Lett. 2004 Sep 20;14(18):4607-13.

PMID:
15324874
17.

2,1,3-Benzothiadiazine derivatives: synthesis and screening versus PDE4 enzyme.

Tait A, Luppi A, Avallone R, Baraldi M.

Farmaco. 2005 Aug;60(8):653-63.

PMID:
15963514
18.

Discovery of new orally active phosphodiesterase (PDE4) inhibitors.

Ochiai H, Ishida A, Ohtani T, Kusumi K, Kishikawa K, Yamamoto S, Takeda H, Obata T, Nakai H, Toda M.

Chem Pharm Bull (Tokyo). 2004 Sep;52(9):1098-104.

19.

Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.

Andrés JI, Alonso JM, Díaz A, Fernández J, Iturrino L, Martínez P, Matesanz E, Freyne EJ, Deroose F, Boeckx G, Petit D, Diels G, Megens A, Somers M, Van Wauwe J, Stoppie P, Cools M, De Clerck F, Peeters D, de Chaffoy D.

Bioorg Med Chem Lett. 2002 Feb 25;12(4):653-8.

PMID:
11844693
20.

Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.

Van der Mey M, Bommelé KM, Boss H, Hatzelmann A, Van Slingerland M, Sterk GJ, Timmerman H.

J Med Chem. 2003 May 8;46(10):2008-16.

PMID:
12723963
Items per page

Supplemental Content

Support Center